WithdrawnPhase 2

A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

Stopped: Sponsor Decision: The trial has been withdrawn with no plans to continue development.

United States, Puerto Rico0Started 2024-05-01

Plain-language summary

The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. at least 1 documented relapse within the previous year, or
✓. at least 2 documented relapse within the previous 2 years, or
✓. at least 1 active Gd-enhancing brain lesion on an MRI scan in the past 6 months prior to screening.

New T1 Gadolinium (Gd)-enhancing Lesions on Brain Magnetic Resonance Imaging (MRI) Per Scan

Timeframe: Week 8 and Week 12

Number of New and/or Enlarging T2 Lesions

Timeframe: Week 12

NCT IDNCT06104683

SponsorLoxo Oncology, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-01-16